Jasper Therapeutics announced it has repurchased approximately 68.94% of its outstanding warrants issued in a 2025 public offering, paying about $2.76 million in cash. The offer expired on November 7, 2026, and the company expects to complete payments promptly. This move reduces the number of warrants outstanding, potentially impacting future equity dilution. Jasper continues to focus on developing therapies for immune-mediated diseases with several candidates in clinical trials.
Jasper Therapeutics' recent warrant repurchase is noted alongside Pluang's health sector market snapshot. For readers following health stocks, here is Pluang's market snapshot as of Nov 09, 2026 19:41 WIB: out of 150 priced health-sector US stocks tradable on Pluang, 121 rose and 18 fell today. Notable movers include ClearPoint Neuro Inc (CLPT) at USD 8.99 with a 1-day change of +4.53% and a typical hold time of 12 days, Roivant Sciences Ltd. (ROIV) at USD 40.25 with +3.52% change and 15 days hold time, and Nuwellis Inc (NUWE) at USD 4.72 with +3.06% change and 32 days hold time.
Microsoft will retire the backend services for its UWP Map Control and Windows Maps APIs on November 30, 2026, ending map functionality in many Windows desktop and tablet applications. OnTerra Systems, a Microsoft partner, has developed an off-the-sh...
Marengo Therapeutics presented interim Phase 2 results from the STARt-002 trial combining invikafusp alfa, a selective T-cell agonist, with sacituzumab govitecan in metastatic triple-negative and HR-positive/HER2-negative breast cancer. The trial sho...
Holzer & Holzer, LLC announced deadlines for investors to seek lead plaintiff status in shareholder class action lawsuits against The Ensign Group, Netcapital Inc., and Webull Corporation. These lawsuits allege misleading statements and failure to di...
Octave Intelligence plc has introduced Octave Attune Facilities, a cloud-based software solution designed to help organizations manage multiple sites with AI-powered tools. This platform integrates building, space, maintenance, and operational data t...
ITT Inc. reported a strong third quarter with revenue up 44% to over $1.40 billion and adjusted earnings rising 20% to $2.26 per share, driven by the SPX FLOW acquisition and 8% organic growth. Orders surged 58%, supported by aerospace, defense, and ...
